WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Inc Stock Forecast, Predictions & Price Target

Analyst price target for EXEL

Based on 9 analysts offering 12 month price targets for Exelixis Inc.
Min Forecast
$25.00+14.16%
Avg Forecast
$28.11+28.36%
Max Forecast
$32.00+46.12%

Should I buy or sell EXEL stock?

Based on 9 analysts offering ratings for Exelixis Inc.
Strong Buy
Strong Buy
5 analysts 55.56%
Buy
3 analysts 33.33%
Hold
1 analysts 11.11%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EXEL stock forecasts and price targets.

EXEL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-07
lockedlocked$00.00+00.00%2024-02-02
lockedlocked$00.00+00.00%2024-01-30Find Out Why
lockedlocked$00.00+00.00%2023-12-19
lockedlocked$00.00+00.00%2023-12-15
JMP Securities
Top 19%
82
BuyReiterates$27.00+23.29%2023-12-14
Morgan Stanley
HoldMaintains$23.00+5.02%2023-11-02
Guggenheim
Top 16%
85
Strong BuyReiterates$30.00+36.99%2023-10-11
HC Wainwright & Co.
Bottom 2%
2
BuyInitiates Coverage On$28.00+27.85%2023-09-26
Truist Securities
Top 12%
89
Strong BuyReiterates$32.00+46.12%2023-09-13

1 of 1

Forecast return on equity

Is EXEL forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.47%

Forecast return on assets

Is EXEL forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

EXEL revenue forecast

What is EXEL's revenue in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$1.9B+4.27%
Avg 2 year Forecast
$2.1B+14.22%
Avg 3 year Forecast
$2.3B+27.78%
EXEL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EXEL earnings growth forecast

How is EXEL forecast to perform vs Biotechnology companies and vs the US market?
Company
55.63%
Industry
6.72%
Market
22.38%
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

EXEL revenue growth forecast

How is EXEL forecast to perform vs Biotechnology companies and vs the US market?
Company
8.3%
Industry
46.57%
Market
10.79%
EXEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EXEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EXEL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EXEL$21.90$28.11+28.36%Strong Buy
IONS$45.21$55.67+23.13%Buy
CRSP$84.22$81.80-2.87%Buy
BBIO$34.15$45.00+31.77%Strong Buy
JAZZ$118.90$186.88+57.17%Strong Buy

Exelixis Stock Forecast FAQ

Is Exelixis Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: EXEL) stock is to Strong Buy EXEL stock.

Out of 9 analysts, 5 (55.56%) are recommending EXEL as a Strong Buy, 3 (33.33%) are recommending EXEL as a Buy, 1 (11.11%) are recommending EXEL as a Hold, 0 (0%) are recommending EXEL as a Sell, and 0 (0%) are recommending EXEL as a Strong Sell.

If you're new to stock investing, here's how to buy Exelixis stock.

What is EXEL's revenue growth forecast for 2024-2026?

(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 8.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.79%.

Exelixis's revenue in 2024 is $1,830,208,000.On average, 10 Wall Street analysts forecast EXEL's revenue for 2024 to be $578,604,705,688, with the lowest EXEL revenue forecast at $560,075,594,938, and the highest EXEL revenue forecast at $592,041,365,664. On average, 9 Wall Street analysts forecast EXEL's revenue for 2025 to be $633,815,773,863, with the lowest EXEL revenue forecast at $599,563,615,230, and the highest EXEL revenue forecast at $686,695,581,381.

In 2026, EXEL is forecast to generate $709,044,939,795 in revenue, with the lowest revenue forecast at $628,154,833,854 and the highest revenue forecast at $794,835,877,739.

What is EXEL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: EXEL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is EXEL's Price Target?

According to 9 Wall Street analysts that have issued a 1 year EXEL price target, the average EXEL price target is $28.11, with the highest EXEL stock price forecast at $32.00 and the lowest EXEL stock price forecast at $25.00.

On average, Wall Street analysts predict that Exelixis's share price could reach $28.11 by Feb 7, 2025. The average Exelixis stock price prediction forecasts a potential upside of 28.36% from the current EXEL share price of $21.90.

What is EXEL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: EXEL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.